Detail akcie TuHURA Bio Rg online

Business Summary: TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, TuHURA Biosciences Inc revenues was not reported. Net loss applicable to common stockholders increased 33% to $30.1M. Higher net loss reflects Single operating segment loss increase of 80% to $31.8M, United States segment loss increase of 80% to $31.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.21 to -$0.63.